Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: ChunLab, Streck, Novogene

ChunLab TrueBac ID

Korean bioinformatics firm ChunLab has launched TrueBac ID, a cloud-based platform that combines proprietary algorithms and a manually curated reference database for bacterial identification targeting more than 12,000 species. The system can provide a full identification report within 30 minutes after a user uploads a genome assembly or raw shotgun sequencing data as a FASTQ file. The report provides fully resolved taxonomic classification, antimicrobial resistance genes, and virulence genes to facilitate correct diagnosis and appropriate therapy. In a recently published study, TrueBac ID was able to accurately identify 34 of 36 clinical isolates (94.4 percent) that were not identified using three commercially available MALDI-TOF MS systems. ChunLab said that it is providing the service for free to all users until the end of 2019 with certain restrictions. In 2020, the company plans to add functions such as strain typing to the platform.


Streck ARM-D Kits; RNA Complete BCT

Streck this week launched three new real-time PCR antibiotic resistance kits for research use only. The kits cover MCR, expanded OXA, and TEM/SHV/GES to detect variants of resistance genes considered by the US Centers for Disease Control.

Streck also introduced RNA Complete BCT, a direct-draw whole-blood collection tube containing a specially designed reagent which maintains the draw-time concentration of extracellular vesicles such as exosomes for up to 7 days at room temperature storage.


Novogene NovoPM 2.0 Cancer Panel

Chula Vista, California-based Novogene has launched its NovoPM 2.0 Cancer Panel, a next-generation sequencing panel that analyzes 484 solid tumor-related genes and introns in 43 genes. According to the firm, the test can detect four types of genomic abnormalities (single nucleotide variation, insertions/deletions, copy number variation, and fusions), and features bioinformatics software including three algorithms specific for guiding cancer immunotherapy decision making.


For more new products and services, please visit the New Products page on our website.